Bio-Protocol (Apr 2021)

Optimized Recombinant Production of Secreted Proteins Using Human Embryonic Kidney (HEK293) Cells Grown in Suspension

  • Silvia Faravelli,
  • Matteo Campioni,
  • Martina Palamini,
  • Anselmo Canciani,
  • Antonella Chiapparino,
  • Federico Forneris

DOI
https://doi.org/10.21769/BioProtoc.3998
Journal volume & issue
Vol. 11, no. 8

Abstract

Read online

Recombinant proteins are an essential milestone for a plethora of different applications ranging from pharmaceutical to clinical, and mammalian cell lines are among the currently preferred systems to obtain large amounts of proteins of interest due to their high level of post-translational modification and manageable large-scale production. In this regard, human embryonic kidney 293 (HEK293) cells constitute one of the main standard lab-scale mammalian hosts for recombinant protein production since these cells are relatively easy to handle, scale-up, and transfect. Here, we present a detailed protocol for the cost-effective, reproducible, and scalable implementation of HEK293 cell cultures in suspension (suitable for commercially available HEK293 cells, HEK293-F) for high-quantity recombinant production of secreted soluble multi-domain proteins. In addition, the protocol is optimized for a Monday-to-Friday maintenance schedule, thus simplifying and streamlining the work of operators responsible for cell culture maintenance.Graphic abstract:Schematic overview of the workflow described in this protocol